Compugen (NASDAQ:CGEN) will be issuing its n/a quarterly earnings data before the market opens on Wednesday, February 21st.
Compugen (NASDAQ:CGEN) opened at $3.10 on Tuesday. Compugen has a 52 week low of $2.25 and a 52 week high of $5.40. The firm has a market capitalization of $158.51, a PE ratio of -4.37 and a beta of 0.68.
CGEN has been the subject of several research reports. Zacks Investment Research raised Compugen from a “hold” rating to a “buy” rating and set a $3.75 target price for the company in a research note on Friday, January 19th. ValuEngine cut Compugen from a “sell” rating to a “strong sell” rating in a research note on Sunday, December 31st.
TRADEMARK VIOLATION NOTICE: This report was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this report on another site, it was stolen and republished in violation of US & international trademark & copyright law. The original version of this report can be accessed at https://www.dispatchtribunal.com/2018/02/20/compugen-cgen-set-to-announce-quarterly-earnings-on-wednesday.html.
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company’s pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates.
Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.